journal article·2019-12-04Open access

Efficacy and safety of nanoparticle albumin-bound paclitaxel in non-small cell lung cancer: a systematic review and meta-analysis

Hong Tan, Jing Hu, Shan Liu

Abstract

Nanoparticle albumin-bound paclitaxel (Nab-paclitaxel) offer more efficient paclitaxel delivery into tumor cells with fewer side effects than conventional chemotherapies. However, whether the efficacy of Nab-paclitaxel for non-small cell lung cancer (NSCLC) patients is age-related remains unknown. We performed this meta-analysis to evaluate the anticancer efficacy and safety of Nab-paclitaxel in NSCLC. Hazard ratios (HRs) or rate ratios (RRs) with corresponding 95% confidence intervals (CIs) for outcomes were retrieved. Thirteen high-quality studies with 4613 patients were included, of which five were comparative trials comparing nab-paclitaxel plus carboplatin (nab-P/C) with solvent-based paclitaxel plus carboplatin (sb-P/C), and the others were non-comparative trials investigating the nab-paclitaxel efficacy. Pooled comparative trial estimates showed that nab-P/C significantly improved overall response rates ([RR]: 1.31) and prolonged progression-free survival (PFS) (HR: 0.89) and overall survival (OS) (HR: 0.93) compared with the control. However, meta-analysis of the younger subgroup indicated that PFS (HR: 93) and OS (HR: 96) were similar between the two arms. Regarding safety, nab-paclitaxel significantly increased risk for grade ≥3 anaemia. For non-hematological adverse events, grade ≥3 sensory neuropathy and arthralgia occurred more frequently in the control arm than in the experimental arm. In conclusion: Nab-paclitaxel is effective and safe for NSCLC patients, especially the elderly.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Lung Cancer Treatments and Mutations · Lung Cancer Research Studies · Cancer Treatment and Pharmacology

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of General Surgery, Chengdu Integrated TCM & Western Medicine Hospital (Chengdu First People's Hospital)

Key Laboratory of Clinical Laboratory Diagnostics (Ministry of Education), College of Laboratory Medicine Chongqing Medical University

Department of Laboratory Medicine, Affiliated Hospital of University of Electronic Science and Technology, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital

References (27)

Show source-provided references
1. 10.3322/caac.2010710.3322/caac.20107 ↗
2. 10.6004/jnccn.2013.008410.6004/jnccn.2013.0084 ↗
3. 10.1021/ja00738a04510.1021/ja00738a045 ↗
4. 10.1634/theoncologist.4-5-40810.1634/theoncologist.4-5-408 ↗
5. 10.2165/00003088-200342070-0000510.2165/00003088-200342070-00005 ↗
6. 10.1200/JCO.1990.8.7.126310.1200/JCO.1990.8.7.1263 ↗
7. Sparreboom A, van Zuylen L, Brouwer E, et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res. 1999;59:1454–1457.
8. 10.1158/1078-0432.CCR-07-459210.1158/1078-0432.CCR-07-4592 ↗
9. 10.1046/j.1445-2197.2003.02748.x10.1046/j.1445-2197.2003.02748.x ↗
10. 10.1016/j.lungcan.2013.02.02010.1016/j.lungcan.2013.02.020 ↗
11. 10.1093/annonc/mds46110.1093/annonc/mds461 ↗
12. 10.1016/j.cllc.2016.04.00210.1016/j.cllc.2016.04.002 ↗
13. 10.1016/j.cllc.2014.09.00310.1016/j.cllc.2014.09.003 ↗
14. 10.1200/JCO.2011.39.584810.1200/JCO.2011.39.5848 ↗
15. 10.1093/annonc/mdl10410.1093/annonc/mdl104 ↗
16. 10.1097/JTO.0b013e3181c0a2f410.1097/JTO.0b013e3181c0a2f4 ↗
17. Xing PY, Li JL, Wang Y, et al. Efficacy and safety of albumin-bound paclitaxel in treating recurrent advanced non-small-cell lung cancer. Chin J Cancer Res. 2013;25:200–205.
18. 10.7314/APJCP.2014.15.17.745310.7314/APJCP.2014.15.17.7453 ↗
19. 10.2147/CIA.S9736310.2147/CIA.S97363 ↗
20. 10.7555/JBR.26.2011010610.7555/JBR.26.20110106 ↗
21. 10.3892/ol.2017.599810.3892/ol.2017.5998 ↗
22. 10.1634/theoncologist.2017-005910.1634/theoncologist.2017-0059 ↗
23. 10.1371/journal.pone.008190310.1371/journal.pone.0081903 ↗
24. 10.1016/S0021-9258(17)37571-310.1016/S0021-9258(17)37571-3 ↗
25. 10.1158/1078-0432.CCR-05-163410.1158/1078-0432.CCR-05-1634 ↗
26. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46:6387–6392.
27. 10.3747/co.21.199710.3747/co.21.1997 ↗